To this end, we coupled peptide 5a to human serum albumin (HSA), to increase the peptide plasma half-life and tested its ability to block TGFβ activation in various in vitro and in vivo tumor models and induce anti-tumor effects. The gene discussed is TGFB1; the disease is neoplasm.